A series of novel inhibitors of lipoprotein associated phospholipase A2 were isolated from the culture broths of Pseudomonas fluorescens strain DSM11579. The inhibitors fall into two structurally isomeric classes each of which comprise compounds incorporating glycosylated hydrocarbon chains. Lipoprotein associated phospholipase A2 (LpPLA2) is the enzyme responsible for hydrolysis of modified oxidised phospholipids from modified low density lipoprotein causing the release of pro-inflammatory lyso-phosphatidyl choline and oxidatively modified fatty acids. Inhibition of LpPLA2 could therefore form a novel therapeutic strategy in the treatment of diseases that have an inflammatory component such as atherosclerosis. In the course of screening to obtain LpPLA2 inhibitors from microorganisms, two series of metabolites of Pseudomonas fluorescens strain DSM11579 showed potent inhibitory activity. The taxonomy and fermentation of the producing strain, the isolation of novel LpPLA2 inhibitors and their biological activities are reported in the preceding article. In this article the physico-chemical properties and structure elucidation of the major metabolite of each class are presented. Biotransformation to produce non-glycosylated analogues provided a compound that proved suitable for single crystal X-ray studies and the resulting structure is presented.